NCT01157377View on ClinicalTrials.gov

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

February 28, 2013

Study Completion Date

May 31, 2013

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

AGN-214868

AGN-214868 injected into the bladder.

DRUG

AGN-214868 placebo

AGN-214868 placebo injected into the bladder.

Trial Locations (3)

Unknown

Richmond

Lyon

Amsterdam

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY